Alzheimer's researchers know the disease is caused by toxic beta amyloid and tau lesions, yet, the recent failure of emerging therapies targeting these lesions suggest that successful treatments will require diagnosis of disease at its earliest stages. Now, by using computer-aided drug discovery, researchers are in the process of developing an imaging chemical that attaches predominantly to tau-bearing lesions in living brain, opening the door for earlier diagnosis – and better treatments for tau-involved conditions like Alzheimer’s, frontal temporal dementia and traumatic brain injuries.